Oncologiejournaal 2022 | Longcarcinoom

Prof. dr. Michel van den Heuvel en Daphne Dumoulin gaan in dit oncologiejournaal in op het ASCO-nieuws omtrent het longcarcinoom. Op dinsdag 7 juni werd dit journaal live uitgezonden en hadden kijkers de mogelijkheid om vragen in te sturen. Het programma is nu on demand terug te kijken.

De volgende onderwerpen komen ter sprake:

Vroeg stadium NSCLC

• EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use
• Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816

Kleincellig longcarcinoom

• SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)
• Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study

Gemetastaseerd niet-kleincellig longcarcinoom met KRAS-mutaties

• Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis
• KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation
• Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial

Andere doelgerichte strategieën bij gemetastaseerd niet-kleincellig longcarcinoom

• Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2
• Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study

Bekijk hier het volledige overzicht van onze ASCO 2022 oncologiejournaals en interviews.